- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01736436
APG101 in Myelodysplastic Syndrome (APG101 in MDS)
APG101 in Transfusion-Dependent Patients With Low or Intermediate Risk Myelodysplastic Syndrome
It has been shown in preclinical experiments with bone marrow from patients with myelodysplastic syndrome that APG101 rescues erythrocytes from premature cell death. This is expected to translate in an improved erythropoiesis and ameliorated anemia in MDS patients.
APG101 might, therefore, be a valuable addition to current treatments of low- or intermediate MDS patients suffering from anaemia.
Transfusion-dependent patients with low or intermediate risk MDS according to WHO Prognostic Scoring Scale (WPSS) can be included in this study.
Treatment consists of 100mg APG101 intravenous as a weekly treatment over 12 weeks + 6 months follow up phase.
Primary objective of the trial is safety and tolerability of APG101; secondary objectives are
- Hematologic, cytologic and cytogenetic response rate using modified International Working Group (IWG) response criteria
- Incidence and time to leukemic progression at 37 weeks
- OS (Overall survival) at 37 weeks
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Heidelberg, Germany, 69120
- Universitaetsklinik Heidelberg, Medizinische Klinik V, Haematologie, Onkologie & Rheumatologie
-
Mannheim, Germany, 68167
- Universitaetsmedizin Mannheim, III. Medizinische Klinik, Haematologie und Onkologie
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Signed informed consent
- Male and female patients with cytologically or histologically established diagnosis of de novo MDS according to the WHO-classification, either previously treated or untreated, presenting with low or intermediate risk features according to WHO prognostic status scale (WPSS)
- Diagnosis of MDS with a medullary blast count of less than 5% has to be established or confirmed by bone marrow morphology
- MDS with 5q deletion only if Lenalidomide is not a treatment option
- Red blood cell transfusion dependency of at least 4 units of packed red blood cells (PRBC) during the last 8 weeks before inclusion. Only PRBC transfusions given for a Hb level ≤ 9g/dl or a haemoglobin level > 9g/dl, if clinically indicated (e.g. coronary heart disease, long distance travel), will count.
- Patients refractory to Erythropoietin-stimulating agents (ESA) (as assessed after at least 8 weeks of treatment) or with a low possibility to respond to ESA treatment
- at least 18 years old, smoking or non-smoking, of any ethnic origin
- ECOG performance status ≤ 2
- Suitable veins or existing port system for intra-venous infusion
- Adequate contraception
Exclusion Criteria:
- Any serious medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from signing the informed consent form
- MDS with medullary blast count ≥ 5%
- Chronic monomyeloic leucemia (CMML)
- Therapy-related / secondary MDS
- High-risk karyotype according to WPSS
- Patients scheduled for bone marrow or stem cell transplant within the next 6 months
- Parallel treatment with ESA or with other experimental therapy
- Prior chemotherapy (including Vidaza)
- Treatment within the last 6 weeks with histone deacetylase (HDAC) inhibitors or ESAs
- Treatment within any other clinical trial parallel to the treatment phase of the current study or within 30 days before inclusion
- Active uncontrolled infection
- HIV, active hepatitis B virus (HBV) and/or hepatitis C virus (HCV) infection
- Any other condition / treatment or past medical history of diseases with poor prognosis that, in the opinion of the investigator, might interfere with the study
- History of or current drug or substance abuse
- History of other (haemato-) oncological disease (except for non-melanoma skin cancer and adequately treated in situ carcinoma of the cervix)
- Inability to understand the protocol requirements, instructions and study-related restrictions, the nature, scope, and possible consequences of the study
- Unlikely to comply with the protocol requirements, instructions and study-related restrictions; e.g., uncooperative attitude, inability to return for follow-up visits, and improbability of completing the study
- Subject is the investigator, research assistant, pharmacist, study coordinator, other staff or relative thereof directly involved in the conduct of the study.
- Hypersensitivity to recombinant proteins or excipients in the investigational drug
- Pregnancy or breast feeding
- Vulnerable patients (e.g., minors or persons kept in detention)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: 100 mg APG101 weekly over 12 weeks
Single arm open label study.
Patient receive 100 mg APG101 i.v.
weekly over 12 weeks with a 6 monthly follow-up phase
|
Patients will be treated 12 weeks with 100 mg APG101 intravenous weekly
During the study, bone marrow will be collected 4 times to assess study objectives
During the study, blood will be drawn at different time points to assess study objectives
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety and tolerability
Time Frame: During the whole study (37 weeks)
|
Evaluation of adverse events (AEs) and serious adverse events (SAEs). Evaluation of electrocardiograms (ECGs), abdominal ultrasound, anti-drug antibodies (ADA), changes in lymphocyte subpopulations / activation markers and changes in performance status (ECOG). Any side effects potentially related to the APG101 treatment are evaluated. |
During the whole study (37 weeks)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall survival (OS)
Time Frame: OS is captured for 37 weeks (during study)
|
Overall survival (OS) is defined as time from start of study treatment to death from any cause
|
OS is captured for 37 weeks (during study)
|
Changes in transfusion frequency
Time Frame: During the whole study. Baseline values are compared to values under treatment with APG101 (e.g baseline compared to week 12 and week 37)
|
Changes in transfusion frequency will be evaluated as those are early signs of an improval in erythropoiesis
|
During the whole study. Baseline values are compared to values under treatment with APG101 (e.g baseline compared to week 12 and week 37)
|
Changes of different parameters (e.g. histologic, cytologic, cytogenetic) in bone marrow according to Chesson criteria
Time Frame: During the study (37 weeks)
|
By assessing different parameters (cytologic, hematologic, cytogenetic), safety as well as efficacy of treatment with APG101 can be evaluated
|
During the study (37 weeks)
|
Changes in hemoglobin (Hb) level
Time Frame: During the study (37 weeks)
|
Changes in Hb level will be evaluated as those are early signs of an improval in erythropoiesis
|
During the study (37 weeks)
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Florian Nolte, MD, Universitaetsmedizin Mannheim, III. Medizinische Klinik, Hämatologie und Onkologie, Theodor-Kutzer-Ufer 1-3, 68167 Mannheim, Germany
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- APG101_CD_003
- 2012-003027-37 (EUDRACT_NUMBER)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Myelodysplastic Syndrome
-
Brian JonasNational Cancer Institute (NCI); Celgene; Pharmacyclics LLC.CompletedPreviously Treated Myelodysplastic Syndrome | Myelodysplastic Syndrome | Therapy-Related Myelodysplastic Syndrome | Secondary Myelodysplastic Syndrome | Refractory High Risk Myelodysplastic SyndromeUnited States
-
Thomas Jefferson UniversityAbbVieRecruitingMyelodysplastic Syndrome | Recurrent Myelodysplastic Syndrome | Refractory Myelodysplastic SyndromeUnited States
-
Uma BorateRecruitingTherapy-Related Myelodysplastic Syndrome | Secondary Myelodysplastic SyndromeUnited States
-
University Hospital, BrestRecruitingMyelodysplastic Syndromes | Myelodysplastic Syndrome With Isolated Del(5Q) | Myelodysplastic Syndrome With Del(5Q)France
-
Cyclacel Pharmaceuticals, Inc.SuspendedLeukemia | Myelodysplastic Syndrome(MDS)United States
-
TJ Biopharma Co., Ltd.Recruiting
-
National Heart, Lung, and Blood Institute (NHLBI)National Cancer Institute (NCI)RecruitingMyelodysplastic Syndromes (MDS)United States, Israel
-
AbbVieCelgene; Genentech, Inc.CompletedMyelodysplastic Syndromes (MDS)United States, Australia, Germany
-
AbbVieGenentech, Inc.Active, not recruitingMyelodysplastic Syndromes (MDS)United States, Australia, Canada, France, Germany, Italy, United Kingdom
-
The First Affiliated Hospital with Nanjing Medical...UnknownMyelodysplastic Syndromes (MDS)China
Clinical Trials on Treatment with APG101
-
CANbridge Life Sciences Ltd.Recruiting
-
CANbridge Life Sciences Ltd.Completed
-
Universidad Complutense de MadridRecruitingMalocclusion, Angle Class II | DistalizationSpain
-
Helsinki University Central HospitalActive, not recruitingto Omit Radioiodine Treatment Safely in Patients With Low -Risk Papillary Thyroid Cancer With Seize of 11-20mm
-
University Hospital, LilleMinistry of Health, France; Laboratoire français de Fractionnement et de BiotechnologiesTerminatedHeart FailureFrance
-
Odense University HospitalNovo Nordisk A/S; Department of Nephrology, Odense University Hospital; The A... and other collaboratorsRecruitingKidney Failure, Chronic | Kidney Injury | Risk Reduction | Contrast-induced NephropathyDenmark
-
University of Roma La SapienzaUnknownCoronary Artery DiseaseItaly
-
The Metis FoundationUnited States Army Institute of Surgical ResearchCompletedHypertrophic ScarUnited States
-
Medical University of GrazRecruitingCarpal Tunnel SyndromeAustria